NewAmsterdam drug cuts cholesterol, but by less than expectations, in phase 3 test

NewAmsterdam Pharma’s drug reduced cholesterol in patients with a genetic disorder by 41% at Week 52, confirming the therapy’s efficacy but falling outside of the range shown in a previous study.